Search alternatives:
teer decrease » greater decrease (Expand Search)
mean decrease » a decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
5 c » 25 c (Expand Search)
teer decrease » greater decrease (Expand Search)
mean decrease » a decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
5 c » 25 c (Expand Search)
-
201
m<sup>5</sup>C modified sites contributes to HBV replication in cccDNA-like system.
Published 2023Subjects: -
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
Overexpressions of the AB domain of RPA70 and the β-barrel domain of Ku70 significantly decrease HBoV1 replication in HAE-ALI.
Published 2022“…At 2 days post-treatment, the cells were probed for expression of mCherry, RPA70-AB, and Ku70-β-barrel by Western blotting using anti-Strep. β-actin was reprobed as loading controls. <b>(C-E) Overexpression of RPA70-AB, and Ku70-β-barrel domains in HAE-ALI decrease the HBoV1 apical virus release and viral genome replication.…”
-
212
Spatial training decreases the association between Ndfip1 and Nedd4 and decreases endogenous Beclin 1 ubiquitination in the hippocampus.
Published 2023“…Endogenous Beclin 1 ubiquitination level is decreased in Nedd4 siRNA-transfected rats (t<sub>1,6</sub> = 5.78, <i>p</i> = 0.001). …”
-
213
-
214
-
215
Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3.
Published 2019“…Significant difference from the control was calculated using one-sample Student’s t-test (* P<0.05). (C) Relative quantification of 5S rRNA in CHX-treated DAOY cells (6 and 14 hours post treatment; 100 μg/ml) using the Δ-c<sub>t</sub> method. …”
-
216
-
217
-
218
-
219
-
220
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: